海思科：获得四款创新药《药物临床试验批准通知书》

Core Viewpoint - The company Haikang Technology (海思科) announced that its subsidiary, Shanghai Haikang Shengnuo Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of multiple drug candidates [1] Group 1 - The approved drug candidates include HSK45019 tablets, HSK50042 tablets, injectable HSK55718, and HSK36357 capsules [1]